Physician

Mamta Tarak Choksi, M.D.

According to 2025 Medicare claims, Mamta Choksi, M.D. (NPI: 1780644351) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Pasco, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34655-1808.

Choksi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 604 traditional Medicare patients, billed 171,336 HCPCS/CPT codes, and received $1,880,273 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 694 prescription claims across 159 beneficiaries totaling $3,136,791 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 31 claims. Open Payments data shows 162 records totaling $3,025. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $625,658 to $3,136,791. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	520	144,493	$1,321,932
2016	573	154,694	$1,491,936
2017	778	156,553	$1,793,121
2018	885	199,623	$2,439,657
2019	963	195,696	$2,299,117
2020	809	192,546	$2,631,881
2021	836	179,164	$2,266,228
2022	589	135,186	$1,793,506
2023	640	149,722	$1,537,533
2024	604	171,336	$1,880,273

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	738	$625,658
2016	141	849	$573,202
2017	117	821	$490,643
2018	128	580	$673,568
2019	121	518	$1,078,944
2020	109	495	$1,226,462
2021	93	371	$1,127,898
2022	98	462	$1,515,777
2023	150	580	$2,123,722
2024	159	694	$3,136,791

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	74	$19,351
2016	N/R	97	$4,390
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	13	$188
2020	N/R	31	$1,565
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	644	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	171	341	$67
96372	Injection of drug or substance under skin or into muscle	161	652	$10
36415	Insertion of needle into vein for collection of blood sample	486	1,237	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	478	1,292	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	38	1,064	$617,248
Ayvakit	Avapritinib	12	360	$474,633
Tasigna	Nilotinib Hcl	30	840	$423,620
Doptelet	Avatrombopag Maleate	11	328	$261,871
Brukinsa	Zanubrutinib	11	330	$166,245

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	162	$3,025	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mamta Tarak Choksi, M.D.?

Tedicare shows public-source Medicare data for Mamta Tarak Choksi, M.D. (NPI 1780644351), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mamta Tarak Choksi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mamta Tarak Choksi, M.D.?

Mamta Tarak Choksi, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Mamta Tarak Choksi, M.D. have Open Payments data?

Mamta Tarak Choksi, M.D. has 162 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.